Citius Hits Primary, Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

 

• Trial achieves statistically significant primary endpoint (p=0.0006)
• Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients retaining their catheters (p=0.0025)

https://www.biospace.com/article/releases/citius-pharmaceuticals-achieves-primary-and-secondary-endpoints-in-phase-3-trial-of-mino-lok-antibiotic-lock-solution/